Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TLSI
Upturn stock ratingUpturn stock rating

TriSalus Life Sciences Inc. (TLSI)

Upturn stock ratingUpturn stock rating
$3.88
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TLSI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.31

1 Year Target Price $11.31

Analysts Price Target For last 52 week
$11.31 Target price
52w Low $3.42
Current$3.88
52w High $5.99

Analysis of Past Performance

Type Stock
Historic Profit -17.6%
Avg. Invested days 64
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 147.35M USD
Price to earnings Ratio -
1Y Target Price 11.31
Price to earnings Ratio -
1Y Target Price 11.31
Volume (30-day avg) 8
Beta 0.48
52 Weeks Range 3.42 - 5.99
Updated Date 08/15/2025
52 Weeks Range 3.42 - 5.99
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.15

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -86.61%
Operating Margin (TTM) -65.39%

Management Effectiveness

Return on Assets (TTM) -52.51%
Return on Equity (TTM) -496.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 154518162
Price to Sales(TTM) 4.09
Enterprise Value 154518162
Price to Sales(TTM) 4.09
Enterprise Value to Revenue 4.29
Enterprise Value to EBITDA -5.96
Shares Outstanding 37975800
Shares Floating 36185692
Shares Outstanding 37975800
Shares Floating 36185692
Percent Insiders 40.56
Percent Institutions 9.02

ai summary icon Upturn AI SWOT

TriSalus Life Sciences Inc.

stock logo

Company Overview

overview logo History and Background

TriSalus Life Sciences Inc. is a commercial-stage oncology company dedicated to developing and commercializing novel delivery systems designed to improve patient outcomes. The company focuses on addressing limitations in current cancer treatment methods by enhancing drug delivery directly to tumors.

business area logo Core Business Areas

  • TriNav Infusion System: The TriNav Infusion System is a proprietary, pressure-enabled drug delivery system designed to administer therapeutic agents directly into a tumor's blood supply.
  • OncoPreTherapy: OncoPreTherapy is a platform that focuses on priming the tumor microenvironment to enhance the effectiveness of subsequent therapies.

leadership logo Leadership and Structure

The leadership team includes Mary Szela (CEO), and other key executives. The company operates with a structure focused on research and development, clinical trials, commercialization, and manufacturing.

Top Products and Market Share

overview logo Key Offerings

  • TriNav Infusion System: The TriNav Infusion System delivers targeted therapy directly to liver tumors. Market share data is not explicitly public. The competitors include companies that offer drug-eluting beads and other intra-arterial therapies for liver cancer like Boston Scientific (BTX) and Merit Medical Systems (MMSI).
  • MATCH-BT (Bronchial Tree) Kit: A microcatheter and guidewire for targeted delivery of therapeutics to treat lung cancer with advanced interventional techniques. Market share data is not publicly available. Competitors also include Boston Scientific (BTX) and Merit Medical Systems (MMSI).

Market Dynamics

industry overview logo Industry Overview

The oncology drug delivery market is experiencing growth driven by the increasing prevalence of cancer, advancements in targeted therapies, and the need for more effective treatment options with reduced side effects.

Positioning

TriSalus Life Sciences Inc. is positioned as an innovator in targeted drug delivery for cancer treatment. Their pressure-enabled drug delivery system aims to overcome limitations of traditional methods and improve therapeutic outcomes.

Total Addressable Market (TAM)

The TAM for targeted drug delivery in oncology is estimated to be billions of dollars. TriSalus is positioned to capture a portion of this market by addressing unmet needs in liver and lung cancer treatment.

Upturn SWOT Analysis

Strengths

  • Proprietary pressure-enabled drug delivery technology
  • Focus on unmet needs in cancer treatment
  • Experienced leadership team
  • Potential for improved therapeutic outcomes

Weaknesses

  • Limited commercial history
  • Dependence on key products
  • Requires significant investment in R&D and clinical trials
  • Highly competitive market

Opportunities

  • Expansion into new cancer indications
  • Partnerships with pharmaceutical companies
  • Increased adoption of targeted therapies
  • Positive clinical trial results

Threats

  • Competition from established players
  • Regulatory hurdles
  • Reimbursement challenges
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • BTX
  • MMSI
  • Varian Medical Systems (VAR)
  • Siemens Healthineers (SEMHF)

Competitive Landscape

TriSalus Life Sciences Inc. possesses innovative targeted drug delivery technology giving it an edge. However it also faces competition from larger well-established medical device companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to its status as a relatively new public company and clinical stage company.

Future Projections: Future growth projections are based on the success of clinical trials, regulatory approvals, and commercial adoption of TriNav and MATCH BT kit. Analyst estimates are not readily available due to limited coverage.

Recent Initiatives: Recent initiatives include advancing clinical trials for TriNav and MATCH BT kit, expanding partnerships, and scaling up manufacturing capabilities.

Summary

TriSalus Life Sciences is a newly public, clinical-stage oncology company with innovative drug delivery technology, particularly its TriNav Infusion System and MATCH BT kit. This technology holds promise for improving cancer treatment outcomes. However, the company faces risks related to regulatory approvals, market adoption, and competition from larger, well-established medical device companies. The long-term success of TriSalus depends on positive clinical trial results and successful commercialization efforts.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Market Research Reports
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About TriSalus Life Sciences Inc.

Exchange NASDAQ
Headquaters Westminster, CO, United States
IPO Launch date 2023-08-10
CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A.
Sector Healthcare
Industry Medical Devices
Full time employees 110
Full time employees 110

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.